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Abstract 
We present a case report of a 45-year old man
who sustained a central dislocation of the hip
secondary  to  an  insufficiency  fracture  of  the
acetabulum. At the time of presentation he was
on alendronate therapy for osteoporosis which
had been previously investigated. CT scanning
of the pelvis was useful for pre-operative plan-
ning which confirmed collapse of the femoral
head  but  no  discontinuity  of  the  pelvis.  The
femoral head was morcellized and used as bone
graft  for  the  acetabular  defect  and  an  unce-
mented total hip replacement was performed. 
Introduction
Insufficiency fractures occur more common-
ly  in  elderly  female  patients  suffering  from
osteoporosis. The incidence of fragility frac-
tures in the UK is increasing due largely to the
rising average age of the population, despite
the  advent  of  newer  anti-osteoporosis  drugs
such as the bisphosphonates. 
Discussion of side-effects  associated with
the use of bisphosphonate therapy has focused
on  the  question  –  can  inhibition  of  bone
turnover  be  harmful?  The  consequences  of
bone turnover inhibition include an increase
in  mineralization  and  an  accumulation  of
micro-damage.  With  this  increase  in  bone
mineralization, the bone becomes more brittle
and  it  may  be  more  susceptible  to  fracture.
This has been shown by biomechanical studies
of a variety of bone samples that show a wide
range  of  mineralization.
1 Regular  physical
stresses may cause micro-damage to normal
bone; however, osteocytes initiate bone remod-
eling whereby they dissolve the damaged bone
and allow osteoblast activity to continue. This
daily damage cannot be repaired if osteoclast
activity is inhibited. High doses of bisphospho-
nates given to animal models have shown an
accumulation  of  micro-damage.
2 This  report
presents an unusual case of a 45-year old male
with known osteoporosis who sustained a cen-
tral dislocation of his left hip secondary to a
stress fracture of the acetabulum. 
Case Report
A 45-year old male was initially referred to
the  clinic  for  increasing  lower  back  pain.
Examination  showed  inability  to  comfortably
weight bear on the left side with posterior hip
pain, an irritable hip with a mild reduction in
the range of movement and equal leg lengths,
and multilevel lumbar spine tenderness with
poor straight leg raise. He was known to have
chronic lower back pain. He was not on any
other regular medications. Initial MRI scan of
the spine (Figure 1) in 2006 revealed signifi-
cant crush fractures to L2 and L4 vertebrae.
Consequently, he was investigated for osteo-
porosis and myeloma with the latter being firm-
ly  excluded.  A  diagnosis  of  osteoporosis  was
confirmed  and  treatment  commenced  with
alendronate,  vitamin  D  and  calcium  supple-
ments.  Risk  factors  for  osteoporosis  in  this
gentleman included smoking (10 cigarettes per
day) and alcohol consumption (40 units of alco-
hol per week). The pain relating to the verte-
bral fracture improved but his left hip pain and
mobility significantly deteriorated. The patient
represented acutely to the fracture clinic. There
was no history of trauma at the time of presen-
tation.  A  plain  X-ray  of  the  pelvis  revealed
marked abnormality at the left hip joint with
central dislocation of the femoral head and pos-
sible  subchondral  collapse  (Figure  2).  A  CT
scan  was  performed  to  further  delineate  the
anatomy of the fracture and aid in pre-opera-
tive  planning  (Figure  3A,  Figure  3B)  which
revealed no pelvic discontinuity. An uncement-
ed total hip replacement was performed and the
femoral head was morcellized and used as bone
graft to reconstruct the acetabulum (Figure 4).
He was advised against weight bearing for six
weeks and then progressed to full weight over a
further six weeks. On X-ray the bone graft had
consolidated at last follow-up and he was able
to fully weight bear without pain.
Discussion
Osteoporosis is characterized by a reduction
in bone mass, leading to increased bone fragility
and risk of fracture. It is usually a disease of the
elderly, in particular in post-menopausal women.
Common risk factors include smoking, alcohol,
low body mass index, long-term corticosteroids
and hypogonadism. Moderate quantities of alco-
hol on a chronic basis have been clearly identi-
fied as a risk factor for the development of osteo-
porosis in young women and men.
3 Acetabular
fractures rarely occur in young patients in the
absence  of  high  energy  trauma.  There  are
reported cases of bilateral central dislocation of
the hips in young patients who have had grand
mal seizures,
4 and patients undergoing electro-
convulsive  therapy.
5 There  are  also  cases  of
acetabular fractures in the elderly due to osteo-
porosis in the absence of any trauma.
6
This case is unusual in view of the young age
of the patient. We believe he developed an insuf-
ficiency fracture of the left acetabulum in the
absence of any precipitating trauma which rap-
idly progressed to a central hip dislocation. 
Pre-operative CT scanning with reconstruc-
tion format was helpful in the delineation of the
fracture pattern and subsequent planning of the
hip reconstruction. There was no evidence of
pelvic  discontinuity  and,  therefore,  the  defect
was filled with morcellized bone graft from the
left femoral head. It is pertinent to note that a
solid  peripheral  fixation  was  possible  with  a
metal acetabular shell and supplemented with
actebular screw fixation. On X-ray the bone graft
was subsequently consolidated and the patient
now is able to fully weight bear without pain.
There  are  still  questions  regarding  the  side-
effects  of  alendronate.
7,8 Like  all  bisphospho-
nates, it acts by inhibiting the action of osteo-
clasts, and has been shown to reduce vertebral
fractures by up to 47% and hip fractures by 51%.
9
However, the inhibition of normal bone turnover
can lead to the accumulation of stress fractures
that do not heal.
8 Goh et al. reported 9 out of 13
patients  who  had  sustained  low  energy  sub-
trochanteric femoral fractures over a period of
ten months and who were taking long-term alen-
dronate.
7They postulated that alendronate was a
contributing factor. Furthermore, Odvina et al.
published a report on 9 patients who sustained
spontaneous non-spinal fractures while on alen-
dronate therapy, 6 of whom displayed delayed
fracture healing for three months to two years
during therapy.
2 Another case report by Cheung
et  al.,  provides  an  example  of  an  82-year  old
woman on alendronate therapy for ten years who
presented with two episodes of non-traumatic
femoral shaft fracture. A bone biopsy performed
suggests adynamic bone disease consistent with
suppressed bone turnover.
10
The effects of bisphosphonate on bone remain
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uncertain.  Profound  suppression  on  the  bone
formation together with its long half-life can lead
to negative effects with its usage.
11 Moreover,
studies have shown the continuing effects of bis-
phosphonate on bone turnover on discontinua-
tion five years previously.
12However, Liberman et
al. argue  that  there  are  no  significant  side
effects  on  bone  health  from  bisphosphonate
therapy.
13 There are studies which suggest bis-
phosphonate prevents local bone loss after total
hip replacements.
14,15 Data from other clinical tri-
als demonstrate that bisphosphonates are bene-
ficial to the bones during the first five years of
use.
16 We cannot firmly associate the acetabular
pathology with the use of bisphosphonates and,
therefore, have continued to treat him with alen-
dronate under multidisciplinary care. 
In conclusion, in this unusual case, we did not
know  whether  alendronate  contributed  to  the
development  of  the  central  dislocation  or
whether  it  was  simply  due  to  minor  trauma
occurring in severely osteoporotic bone. 
References
1. Curry JD. Effect of differences in mineral-
ization  on  the  mechanical  properties  of
bone. Philos Trans R Soc Lond B Biol Sci
1984;304:509-18 
2. Odvina CV, Zerwekh JE, Rao DS, Maalouf N,
Gottschalk  FA,  Pak  CYC.  Severely  sup-
pressed bone turnover: a potential compli-
cation  of  alendronate  therapy.  J  Clin
Endocrinol Metab 2005;90:1294-301
3. Iqbal  MM.  Osteoporosis:  epidemiology,
diagnosis,  and  treatment.  South  Med  J
2000;93:2-18.
4. Remec PT, Evarts CM. Bilateral central dis-
location  of  the  hip.  A  case  report.  Clin
Orthop Relat Res 1983;118-20.
5. Sarpel Y, Togrul E. Herdem M, et al. Central
acetabular  fracture-dislocation  following
electroconvulsive  therapy:  report  of  two
similar cases. J Trauma 1996;41:342-4.
6. Rosa  MA,  Maccauro  G,  D’Arienzo  M.
Bilateral acetabular fracture without trau-
ma. Int Orthop 1999;23:120-1.
7. Goh S-K, Yang KY, Koh JSB, Wong MK et al.
Subtrochanteric  insufficiency  fractures
patients  on  alendronate  therapy.  J  Bone
Joint Surg Br 2007;89:349-53.
8. Mashiba T, Hirano T, Turner CH, Foewood
MR et al. Suppressed bone turnover by bis-
phosphonates  increases  microdamage
accumulation  and  reduces  some  biome-
chanical properties in dog rib. J Bone Miner
Res 2000;15:613-20.
9. Black DM, Cummings SR, Karpf DB, Cauley
JA, et al. Randomised trial of effect of alen-
dronate on risk of fracture in women with
existing  vertebral  fractures.  Fracture
Intervention Trial Research Group. Lancet
1996;348:1535-41.
10. Cheung RK, Leung KK, Lee KC, Chow TC
2007  Sequential  non-traumatic  femoral
shaft fractures in a patient on long-term
alendronate.  Hong  Kong  Journal,  Hong
Kong  Academy  of  Medicine,  December
2007, Vol./is. 13/6, 1024-2708.
11. Susan  M.  Ott.  Long-term  safety  of
Bisphosphanate. J Clin Endocrinol Metabol
2005;90: 1897-9
12. Ensrud KE, Barrett-Connor EL, Schwartz A,
et  al.  Randomized  trial  of  effect  of  alen-
dronate  continuation  versus  discontinua-
tion in women with low BMD: results from
the  Fracture  Intervention  Trial  long-term
extension. J Bone Miner Res 2005;20:895-7.
13. Liberman  UA.  Long-term  safety  of
Bisphosphonate therapy for osteoporosis: a
review  of  the  evidence.  Drug  Aging
2006;23:289-98.
14. Arabmotlagh M, Rittmeister M, Hennigs T.
Alendronate prevents femoral periprosthet-
ic bone loss following total hip arthroplasty.
J Orthop Res 2006;24: 1336-41.
15. Wilkinson  JM,  Stockley  I,  Peel  NF,  et  al.
Effect of pamidronate in preventing local
bone loss after total hip arthroplasty: a ran-
domized,  double-blind,  controlled  trial.  J
Bone Miner Res 2001;16:556-64.
16. Black  D,  Schwartz  A,  Ensrud  K,  Rybak-
Feiglin A, Gupta J, Lombardi A, Wallace R,
Levis S, Quandt S, Satterfield S, Cauley J,
Cummings S. A 5 year randomised trial of
the long-term efficacy and safety of alen-
dronate. J Bone Mineral Res 2004;10:S45.
Case Report
Figure 1. MRI lumbar spine showing verte-
bral fractures at first presentation to clinic.
Figure 4. Post-operative X-ray showing an
uncemented total hip replacement.
Figure 3. CT 3D reconstructions showing
a fracture of the left acetabulum with cen-
tral dislocation of the femoral head.
Figure 2. X-ray showing a fracture of the
left acetabulum with central dislocation of
the femoral head.
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